PAHC:NSD-Phibro Animal Health Corporation (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | NASDAQ Global Market

Last Closing

USD 19.65

Change

-0.22 (-1.11)%

Market Cap

USD 1.11B

Volume

0.12M

Analyst Target

USD 22.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Phibro Animal Health Corp is a diversified animal health and mineral nutrition company. It develops, manufactures and markets products for food animals including poultry, swine and cattle.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 83.17B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.69B
HLN Haleon plc

N/A

USD 47.33B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.37B
CTLT Catalent Inc

N/A

USD 10.83B
ELAN Elanco Animal Health

N/A

USD 7.59B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.67B
BHC Bausch Health Companies Inc

N/A

USD 2.33B
CPHI China Pharma Holdings Inc

N/A

USD 3.04M
YCBD cbdMD Inc

N/A

USD 2.14M

ETFs Containing PAHC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 69.69% 88% B+ 98% N/A
Dividend Return 3.11% 86% B+ 63% D
Total Return 72.80% 88% B+ 98% N/A
Trailing 12 Months  
Capital Gain 52.21% 82% B 94% A
Dividend Return 3.72% 86% B+ 53% F
Total Return 55.93% 82% B 94% A
Trailing 5 Years  
Capital Gain -4.89% 50% F 40% F
Dividend Return 11.62% 80% B- 42% F
Total Return 6.73% 50% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain -10.61% N/A N/A 25% F
Dividend Return -8.16% N/A N/A 26% F
Total Return 2.45% N/A N/A 55% F
Risk Return Profile  
Volatility (Standard Deviation) 20.54% N/A N/A 75% C
Risk Adjusted Return -39.70% N/A N/A 21% F
Market Capitalization 1.11B 33% F 55% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.80 45% 10%
Price/Book Ratio 3.14 50% 28%
Price / Cash Flow Ratio 63.72 8% 4%
Price/Free Cash Flow Ratio 15.34 25% 28%
Management Effectiveness  
Return on Equity 4.85% 67% 42%
Return on Invested Capital 6.94% 58% 56%
Return on Assets 3.84% 50% 65%
Debt to Equity Ratio 160.19% 22% 21%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector